High-tech pharmaceutical company specializing in the development of new drugs for kidney disease and cancer
Location: China, Zhejiang, Hangzhou City
Investors 1
| Date | Name | Website |
| 19.03.2022 | Northern L... | nlvc.com |
Mentions in press and media 4
| Date | Title | Description |
| 29.10.2024 | KIND Presents Positive Results of AND017 to Treat Anemia Associated with Chronic Kidney Disease in Two Phase II and Two Phase I | Clinical Trials at American Society of Nephrology (ASN) – Kidney Week 2024 SAN FRANCISCO, Oct. 29, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biop... |
| 26.10.2024 | KIND Announces FDA Granted Orphan Drug Designation (ODD) for AND017 in the Treatment of Sickle Cell Disease (SCD) | SAN FRANCISCO, Oct. 26, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat h... |
| 17.10.2024 | KIND Announces Late-Breaking Abstract Accepted for Presentation on AND017 Clinical Trials to Treat Anemia in Chronic Kidney Disease (CKD) at ASN - Kidney Week 2024 | SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat h... |
| 17.04.2024 | Kind Pharmaceuticals Announces Settlement | HANGZHOU, China, April 17, 2024 /PRNewswire/ -- Today, Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC ("Kind Pharmaceuticals"), together with its Chief Executive Officer Dr. Dong Liu and Chief Scientific Officer D... |